Success Metrics

Clinical Success Rate

71.4%

Based on 5 completed trials

Completion Rate

71%(5/7)

Active Trials

0(0%)

Results Posted

80%(4 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_3

50%

Ph phase_4

13%

Ph phase_2

13%

Ph phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

1(14.3%)

Phase 3Large-scale testing

4(57.1%)

Phase 4Post-market surveillance

1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(3)

Detailed Status

Completed5

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

71.4%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (14.3%)

Phase 21 (14.3%)

Phase 34 (57.1%)

Phase 41 (14.3%)

Trials by Status

completed563%

terminated225%

withdrawn113%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_2

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

NCT00111891

completedphase_3

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

NCT00378833

completedphase_1

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

NCT01012219

completedphase_3

Lipid Efficacy/Tolerability Study (0524A-020)

NCT00269204

terminated

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

NCT01228019

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT00111891Phase 2

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Completed

NCT00378833Phase 3

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Completed

NCT01012219Phase 1

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Completed

NCT00269204Phase 3

Lipid Efficacy/Tolerability Study (0524A-020)

Completed

NCT01228019

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Terminated

NCT00664287Phase 3

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Withdrawn

NCT00479388Phase 3

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Completed

NCT01239992Phase 4

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Terminated

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8